Table 2.
Summary of study characteristics by the five most common bacteria isolated.
| Characteristic |
P.multocida (n = 221) |
S.aureus (n = 81) |
S.pseudintermedius (n = 50) |
C.canimorsus (n = 49) |
B.bronchiseptica (n = 46) |
|---|---|---|---|---|---|
| Study Design | |||||
| Case report (n = 299) | 192 (86.9%) | 7 (8.6%) | 20 (40.0%) | 42 (85.7%) | 38 (82.6%) |
| Case series (n = 43) | 21 (9.5%) | 6 (7.4%) | 3 (6.0%) | 5 (10.2%) | 8 (17.4%) |
| Cross-sectional/Prevalence (n = 91) | 8 (3.6) | 59 (72.8%) | 22 (44.0%) | 2 (4.1%) | 0 (0.0%) |
| Longitudinal (n = 8) | 0 (0.0%) | 5 (6.2%) | 3 (6.0%) | 0 (0.0%) | 0 (0.0%) |
| Cohort (n = 3) | 0 (0.0%) | 2 (2.5%) | 1 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Case-control (n = 3) | 0 (0.0%) | 2 (2.5%) | 1 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Primary Study Setting | |||||
|
Household/ Community (n = 64) |
9 (4.1%) | 37 (41.6%) | 16 (31.4%) | 2 (4.1%) | 0 (0.0%) |
|
Veterinary clinic/ Veterinary school (n = 48) |
1 (0.5%) | 37 (41.6%) | 10 (19.6%) | 0 (0.0%) | 0 (0.0%) |
| Human hospital/Clinic (n = 334) | 209 (94.6%) | 12 (13.5%) | 22 (43.1%) | 45 (91.8%) | 46 (100.0%) |
| Laboratory (n = 6) | 1 (0.5%) | 1 (1.1%) | 2 (3.9%) | 2 (4.1%) | 0 (0.0%) |
| Other/unknown (n = 4) | 1 (0.5%) | 2 (2.2%) | 1 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Pet Species Sampled | |||||
| Dog (n = 74) | 15 (6.8%) | 34 (42.0%) | 20 (40.0%) | 3 (6.1%) | 2 (4.3%) |
| Cat (n = 28) | 20 (9.0%) | 6 (4.2%) | 0 (0.0%) | 2 (4.1%) | 0 (0.0%) |
| Both (n = 55) | 8 (3.6%) | 35 (43.2%) | 11 (22.0%) | 0 (0.0%) | 1 (2.2%) |
| None (n = 290) | 178 (80.5%) | 6 (7.4%) | 19 (38.0%) | 44 (89.8%) | 43 (93.5%) |
| Antimicrobial Use in Humans and Outcome | |||||
| Yes and died (n = 49) | 26 (11.8%) | 1 (1.2%) | 1 (2.0%) | 11 (22.4%) | 10 (20.8%) |
| Yes and recovered (n = 278) | 178 (80.5%) | 10 (12.3%) | 19 (38.0%) | 35 (71.4%) | 36 (75.0%) |
| Yes and unknown outcome (n = 17) | 10 (4.5%) | 3 (3.7%) | 1 (2.0%) | 1 (2.0%) | 2 (4.2%) |
| No antimicrobial use (n = 5) | 0 (0.0%) | 4 (4.9%) | 1 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Unknown use and outcome (n = 100) | 7 (3.2%) | 63 (77.8%) | 28 (56.0%) | 2 (4.1%) | 0 (0.0%) |
| Immunocompromise Status of Human | |||||
| Yes (n = 110) | 56 (25.3%) | 3 (3.7%) | 7 (14.0%) | 15 (30.6%) | 29 (63.0%) |
| No (n = 77) | 41 (18.6%) | 13 (16.0%) | 8 (16.0%) | 11 (22.4%) | 4 (8.7%) |
| Both (n = 21) | 7 (3.2%) | 4 (4.9%) | 5 (10.0%) | 2 (4.1%) | 3 (6.5%) |
| Unknown (n = 239) | 117 (52.9%) | 61 (75.3%) | 30 (60.0%) | 21 (42.9%) | 10 (21.7%) |
| Evidence of Transmission Assessment | |||||
| Presumptive Transmission (n = 302) | 180 (81.4%) | 9 (11.1%) | 20 (40.0%) | 47 (95.9%) | 46 (100.0%) |
| Low (n = 35) | 19 (8.6%) | 10 (12.3%) | 5 (10.0%) | 1 (2.0%) | 0 (0.0%) |
| Medium (n = 44) | 15 (6.8%) | 20 (24.7%) | 8 (16.0%) | 1 (2.0%) | 0 (0.0%) |
| High (n = 66) | 7 (3.2%) | 42 (51.9%) | 17 (34.0%) | 0 (0.0%) | 0 (0.0%) |